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Abstract  
Many cancer entities and their associated cell line models are highly heterogeneous in their 
responsiveness to apoptosis inducers and, despite a detailed understanding of the underlying 
signalling networks, cell death susceptibility currently cannot be predicted reliably from 
protein expression profiles. Here, we demonstrate that an integration of quantitative apoptosis 
protein expression data with pathway knowledge can predict the cell death responsiveness of 
melanoma cell lines. By a total of 612 measurements, we determined the absolute expression 
(nM) of 17 core apoptosis regulators in a panel of 11 melanoma cell lines, and enriched these 
data with systems-level information on apoptosis pathway topology. By applying multivariate 
statistical analysis and multi-dimensional pattern recognition algorithms, the responsiveness 
of individual cell lines to TRAIL or dacarbazine could be predicted with very high accuracy 
(91% and 82% correct predictions), and the most effective treatment option for individual cell 
lines could be pre-determined in silico. In contrast, cell death responsiveness was poorly 
predicted when not taking knowledge on protein-protein interactions into account (55% and 
36% correct predictions). We also generated mathematical predictions on whether anti-
apoptotic Bcl-2 family members or x-linked inhibitor of apoptosis protein (XIAP) can be 
targeted to enhance TRAIL responsiveness in individual cell lines. Subsequent experiments, 
making use of pharmacological Bcl-2/Bcl-xL inhibition or siRNA-based XIAP depletion, 
confirmed the accuracy of these predictions. We therefore demonstrate that cell death 
responsiveness to TRAIL or DTIC can be predicted reliably in a large number of melanoma 
cell lines when investigating expression patterns of apoptosis regulators in the context of their 
network-level interplay. The capacity to predict responsiveness at the cellular level may 
contribute to personalising anti-cancer treatments in the future. 
Key Words: Systems biology; Cell Death; Apoptosis; Melanoma; Cancer; TRAIL. 
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Introduction 
The past decades of molecular cancer research have demonstrated that many cancer entities, 
including malignant melanoma, are biologically highly heterogeneous. As a consequence of 
biological heterogeneity, only subsets of patient populations benefit from anti-cancer 
chemotherapies. For example, on average only 15% of metastatic melanoma patients respond 
to the standard single-agent chemotherapy based on the proapoptotic alcylating agent 
dacarbazine (DTIC) 1. Likewise, alternative chemotherapeutics or combination treatments 
with DTIC so far did not result in more effective therapies 1. Inter-individual heterogeneity is 
also thought to contribute considerably to the unsustainably high attrition rates of phase II/III 
clinical trials, since cohort recruitment is often not informed by tools that allow to predict 
whether patients are likely to respond to the treatment tested 2. Biological heterogeneity in 
gene and protein expression has been captured in numerous biomarker discovery studies in 
order to identify, by statistical means, whether molecular signatures can predict drug 
responsiveness. However, these traditional approaches so far are rather unsuccessful, with 
most biomarker candidates failing at the clinical validation stage 3. In melanoma, the 
presence of V600E-mutated B-Raf kinase is such a marker, and can be found in 
approximately 50% of patients with advanced disease. Whenever V600E-mutated B-Raf is 
found, the inhibitor Vemurafenib has proved to be a remarkable success as monotherapy 4. 
The remaining patient population, however, still receives DTIC-based chemotherapy or 
immune therapy with ipilimumab, a CTLA-4 antagonizing antibody. Most recently 
combination therapies of programed death (PD) -1 receptor directed antibodies combined 
with ipilimumab showed a dramatic success, indicating that immune-mediated cell death is a 
successful way to control melanoma metastasis 5. Even though deregulations in apoptosis 
signaling are known to limit melanoma responsiveness to various therapies 6, so far no 
apoptosis-related protein expression patterns could be firmly associated with DTIC 
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responsiveness or responsiveness to other apoptosis-inducing agents in patients or cell line 
model systems. A broader multi-parametric system-level approach towards cell death 
signaling in cell line models is therefore warranted and may contribute to informing future 
translational research strategies.  
Apoptosis signals are transduced by two main pathways (extrinsic and intrinsic) which are 
tightly regulated by a complex interplay of multiple proteins 7-8. Therefore, a large number of 
possibilities exist by which apoptosis signal transduction may be impaired. Integrating 
information on protein-protein interplay and pathway topology into data sets on protein 
expression amounts may therefore enhance the capacity of multivariate statistical models to 
accurately and case-specifically predict cell death responsiveness. The perspectives offered 
by systems biological and systems medical approaches 9, and the first successful proof-of-
principle systems medical studies in the field of cancer and apoptosis 10-11 support this notion.  
Here, we therefore developed a system-level approach of knowledge- and data-driven 
multivariate statistical modeling and applied this to a panel of malignant human melanoma 
cell lines in order to identify whether baseline protein expression patterns carry information 
that indicate susceptibility to apoptosis inducing drugs. We were able to reliably predict the 
responsiveness of individual cell lines to known inducers of extrinsic or intrinsic apoptosis 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and DTIC, respectively. 
Predictions were sufficiently accurate to devise a decision tool that identifies the more 
efficient cell death inducer for individual cell lines. For poorly responding cell lines, we 
successfully validated further in silico predictions on which proteins need to be targeted by 
molecular perturbations in order to increase or restore responsiveness to TRAIL.  
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Results 
 
Defining functional groups of apoptosis signalling proteins for a knowledge- and data-
driven systems modelling approach.  
Since decision points in apoptosis signal transduction are under the control of multi-protein 
interactions, we integrated basic pathway knowledge on protein-protein interplay into 
baseline expression data. This was achieved by defining functional groups, each of which 
comprised a limited number of proteins that were related to each other by simple arithmetic 
operations. These operations reflected the functional relationship of these proteins within the 
apoptosis signaling network that is initiated by tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) (Fig.1A). In brief, the TRAIL pathway is induced by TRAIL 
binding to death receptors DR4 and DR5. DR4/5 then recruit the adapter protein FADD and 
form the death-inducing signaling complex (DISC). Caspase-8 is activated on the DISC, but 
caspase-8 activation can be antagonized by competitive binding of the catalytically inactive 
homologue cFLIP. Caspase-8 cleaves and activates the BH3-only protein Bid as well as 
effector caspase-3. Truncated Bid promotes the permeabilisation of the outer mitochondrial 
membrane by activating the pore-forming proteins Bax and Bak, and by inhibiting anti-
apoptotic Bcl-2 family members Bcl-2, Bcl-xL and Mcl-1. Through Bax/Bak pores, 
cytochrome-c (cyt-c) and the XIAP antagonist Smac are released into the cytosol. Cyt-c 
activates Apaf-1, and Apaf-1 oligomerises to form the caspase-9-activating apoptosome 
complex. Caspase-9 proteolytically activates caspase-3, with the inhibitor XIAP suppressing 
caspase activity. Caspase-3 cleaves a large number of target proteins and is the central driver 
of rapid apoptosis execution and cell death 7-8. The intrinsic apoptosis pathway, which is 
induced by various forms of intracellular stresses, feeds in at the level of BH3-only proteins 
other than Bid. These BH3-only proteins are transcriptionally induced, posttranslationally 
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activated or stabilized, and contribute as Bax/Bak activators and/or as Bcl-2/Bcl-xL/Mcl-1 
antagonists. To code this pathway by functional groups, the rationale was to keep these 
groupings arithmetically simple (sums, products or ratios of a small number of proteins), 
biologically justifiable, and to incorporate the expression amount of each protein only once 
(Fig.1B). For example, we defined a functional group that represents the key anti-apoptotic 
Bcl-2 family members by pooling the absolute amounts (nM) of Bcl-2, Bcl-xL and Mcl-1. 
Likewise, we defined a functional group for the mitochondrial Bax/Bak pore formation 
capacity by pooling the amounts of Bax and Bak. By multiplying the amounts of Apaf-1 and 
caspase-9, we defined a functional group that represents the caspase-9-activating apoptosome 
complex. Here, the multiplication ensures that the value for this group approaches zero when 
either Apaf-1 or caspase-9 expression is very low or absent. With similar reasoning, we 
multiplied the pooled DR expression with the amount of FADD to represent the DISC. 
Functional groups of apoptotic caspases and their antagonists were defined as ratios 
(cFLIP/caspase-8 and XIAP/caspase-3). Following these groupings, the three remaining 
proteins (Bid, cyt-c, Smac) were kept as individual variables. While cyt-c is known to be an 
abundant protein 12, only a fraction of the cyt-c pool would be expected to contribute to 
apoptosis signaling. For example, significant amounts of cyt-c may be immobilized by 
cardiolipin interactions 13-14. Likewise, the cyt-c redox status and additional molecular 
interactions in the cytosol following cyt-c release from the mitochondria are not captured in 
this study but may further modify the amount of cyt-c that contributes to apoptosome 
formation 15-17. Such interactions could be merged in the cyt-c functional group in the future. 
Similarly, other proteins not quantified in this study that functionally overlap with Bid or 
Smac, such as other BH3-only proteins or Omi/HtrA2, could form functional groups with 
these in future extended quantification studies (i.e. a functional unit for BH3-only proteins 
and a functional unit for XIAP antagonists).  
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To parameterize the functional groups, we determined the expression profiles of these 17 key 
proteins involved in TRAIL-induced apoptosis signaling in a panel of 11 melanoma cell lines. 
With the exception of DR4 and DR5, whose cell surface expressions were determined by 
indirect immunofluorescence (Supplemental Fig.S1A), all protein amounts were measured by 
quantitative immunoblotting at 12 bit dynamic range (see methods for details; absolute 
protein concentrations are provided as Supplemental Table 1). Representative 8-bit converted 
immunoblotting signals are shown in Supplemental Fig.S1B. An overview of the relative 
protein expression within the melanoma cell line panel, based on 612 quantifications, is 
presented in Fig.1C and demonstrates high heterogeneity across the cell line panel.  
 
Multi-dimensional pattern recognition identifies a relation between functional groups of 
apoptosis regulators and cell death responsiveness to TRAIL and DTIC. 
As part of a data-driven modeling approach 18, we next applied a principle component 
analysis (PCA) 19-20 to the data set of the functional groups. This was followed by the 
integration of drug response data into the PCA output and a spatial segmentation of cell lines 
clusters with similar responsiveness by a pattern recognition approach. A step-by-step 
workflow of the modeling and analysis procedures is provided as Supplemental Figure 2 and 
can be consulted in parallel to the following results section.  
A principal component analysis is a multivariate statistical procedure which reduces the 
dimensionality of complex multi-dimensional data sets by mathematical transformation into 
principle components. Slightly simplified, this transformation can be understood as a rotation 
of the data around their mean so that previously independent variables (the 9 dimensions of 
the functional groups; Fig.1B) now jointly define new axes. These new axes are the principal 
components (PCs) and describe the principal component space. While each PC consists of 
contributions by all variables that are found in the original data set, the contributions of these 
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variables differ for each PC according to specific weighting coefficients, as shown below. 
The PCA is geared towards representing as much of the data variance as possible in the first 
few PCs, thereby making the information content of the remaining PCs largely negligible for 
further analyses and allowing for a dimensionality reduction to a small number of PCs. We 
correspondingly could visualize this when showing the PCA results in a modified scree plot 
(Fig.2A). The first four principle components were required to reflect 85% of the data 
variance found in the functional groups, and these four principle components fulfilled the 
Kaiser criterion 21-22 (Fig.2A). The Kaiser criterion is a decision guideline which states that 
only PCs with an eigenvalue of one or above will need to be used for further analysis as this 
indicates that these PCs contain more information on data variance than a single variable in 
the original data set. The first four principle components were therefore retained for all 
subsequent analyses and procedures. The coefficients for the weightings of the functional 
groups in these PCs are displayed in Fig.2B, and the respective numerical values are provided 
as Supplemental Table 2. The coefficients indicated that the first principle component is 
strongly influenced by multiple functional groups: The anti-apoptotic Bcl-2 family members 
are antagonized by Bax+Bak. Similarly, contributions by the XIAP/caspase-3 ratio are 
antagonized by caspase-9*Apaf-1. (DR4+5)*FADD and Bid are strong contributors to the 
second principle component, as is cyt-c. The cFLIP/casp-8 ratio most prominently influenced 
the fourth principle component. We used the PCs to define a 4-dimensional Euclidean space 
into which we positioned the 11 melanoma cell lines according to the values of their 
functional groups. To this end, the numerical values of the functional groups were multiplied 
with the respective weighting coefficients in the PCs. Associated visualizations naturally had 
to be limited to the first three dimensions, which still reflect 71% of the original data variance 
(Fig2C). Cell lines with similar compositions of the functional groups would have been 
expected to cluster together. However, no obvious clusters could be detected. Rather, cell 
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lines were scattered throughout the PC space (Fig.2C), indicating a high variability in the 
values of the functional groups across the melanoma cell line panel.  
We next investigated whether the spatial positions of the cell lines are related to their cell 
death responsiveness. To this end, we measured the overall cell death induced by TRAIL and 
by DTIC, the standard melanoma chemotherapeutic in B-Raf negative melanoma, in all cells 
lines. DTIC is a pro-drug that is converted intracellularly by mitochondrial cytochrome P450 
to the alkylating agent MTIC, and induces apoptosis through the intrinsic pathway 23. The cell 
death responses to TRAIL and also to DTIC were highly heterogeneous across the cell line 
panel, and individual cell lines typically also presented with different levels of responsiveness 
to TRAIL or DTIC (Fig.2D). Control measurements in presence of pan-caspase inhibitor 
zVAD-fmk in highly responsive cell lines demonstrated that cell death was executed 
primarily by apoptosis (Supplemental Fig.S3). The cell lines in the PC space were then color 
coded according to their TRAIL or DTIC responsiveness (Fig.2E,F). To this end, cell lines 
were defined as being resistant (0-10% cell death; black) or responsive (graded into “low” 
(10-30% cell death; red), “medium” (30-60% cell death; yellow) or “high” (>60% cell death; 
green)). Interestingly, cell lines with a similar TRAIL responsiveness appeared to occupy 
common regions in the 3D PC space (Fig.2E), and these response regions did not intersect 
when visually segmented (see also a 360° rotation provided as Supplemental Movie 1). 
Regions in the 3D PC space that reflect similar drug susceptibility were also found for DTIC 
treatments (Fig.2F). Also these response regions appeared to be separable by visual 
segmentation (best seen in the 360° rotation provided as Supplemental Movie 2 and in a view 
from an alternative angle provided as Supplemental Fig.S4). Corresponding to the cell line 
panel responding differently to TRAIL or DTIC, also the spatial regions that reflect similar 
levels of susceptibility differed between the TRAIL and DTIC (Fig.2E,F; Supplemental 
Movies 1,2).  To determine whether the spatial regions that indicate different levels of drug 
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responsiveness could also be separated objectively, we applied a linear discriminant analysis 
(LDA) to the 4-dimensional PC space. A canonical LDA is a pattern recognition approach 
that mathematically defines linear functions with the aim to optimally separate multiple 
classes of objects in n-dimensional space 24. The LDA working principle is visualised for a 
simplified 2D scenario in Fig.2G. LDA accurately separated the TRAIL response groups: All 
cell lines were correctly classified (Fig.2H). Likewise, a very good separation was achieved 
for DTIC, with 10 out of 11 cell lines correctly classified (91%) (Fig.2H).  
Taken together, we found that spatial regions exist which represent distinct levels of drug 
responsiveness. These spatial regions differ between the drugs investigated, and for each drug 
these can be separated by an objective mathematical pattern recognition approach. Therefore, 
even though the cell lines are very heterogeneous in their protein expression profiles, these 
protein profiles, together with basic pathway knowledge, can be used to relate expression 
patterns to cell death susceptibility with high accuracy.  
 
Case-specific predictions of TRAIL and DTIC responsiveness in malignant melanoma 
cell lines allow the in silico identification of optimal treatments. 
To determine whether our approach has the capacity to predict cell death responsiveness 
case- and drug-specifically, we next applied “leave-one-out” cross-validations (LOOCV). To 
this end, 11 new PCAs were conducted to cover all possible combinations of 10 from the 
pool of melanoma cell lines. Clusters of common responsiveness in each PCA were then 
identified by LDA as described above. The missing cell lines (test cell lines) were positioned 
into the four dimensional PC spaces according to their functional group values, and their 
responsiveness was predicted based on the LDA-defined cluster associated with the PC space 
position. These predictions were validated against experimentally measured cell death 
susceptibility. Exemplary 2D projections of the 3D PC spaces for TRAIL responsiveness 
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demonstrate visually that test cell lines positioned in close proximity to cell lines that were of 
similar responsiveness (Fig.3A). The predictive power of this approach was very high for 
both TRAIL- and DTIC-responsiveness, with 10 and 9 cell lines being positioned in the 
correct LDA-defined response regions (91% and 82% prediction accuracy, respectively) 
(Fig.3B). As a control, we performed the same procedure on the raw protein expression data 
rather than the functional groups data. The accuracy dropped significantly, with the 
responsiveness of only 55% and 36% of the cell lines correctly predicted for TRAIL or DTIC 
treatments, respectively. This highlights that accurate predictions can only be made when 
taking pathway knowledge into account.  
We next investigated whether this predictive capacity is sufficiently high to case-specifically 
determine the optimal treatment in silico. “Optimal treatment” here is defined as the drug that 
evokes the higher amount of cell death, with either drug being an acceptable choice if both 
treatments were predicted to induce comparable amounts of cell death. In contrast, wrong 
predictions would suggest treatments that in experiments induce lower amounts of cell death 
than the alternative treatment option. Cell line-specific treatment suggestions were correct for 
10 out of the 11 cell lines (Fig.4). Only for PM-WK cells the better treatment option was not 
identified. These results indicate that our approach is very powerful in accurately predicting 
drug responsiveness and in exploiting this as a decision tool to select the optimal treatment 
option between TRAIL and DTIC for individual cell lines.  
 
Knowledge- and data-driven systems modeling can predict targeted perturbations that 
sensitize poorly responding melanoma cell lines to TRAIL. 
The positioning of each cell line in the PC space is coded by the values calculated for their 
functional groups. We therefore hypothesized that this information could also be exploited to 
generate case-specific predictions on how to sensitize poor TRAIL responders by targeted 
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drugs or by siRNA-based protein depletion. As a representative targeted drug, we used ABT-
737, a well characterized synthetic antagonist of the anti-apoptotic Bcl-2 family members 
Bcl-2 and Bcl-xL 25 that is currently also tested in clinical trials as a sensitizer of melanoma 
to proliferation inhibitors such as MEK inhibitors 26. To generate predictions on which poorly 
responding cell line can be sensitized by ABT-737, we determined how the position of 
individual cell lines in the PC space would change upon elimination of Bcl-2 and Bcl-xL. The 
vector for the direction of this repositioning can be calculated from the PCA results by 
moving in opposite direction to the coefficients of the targeted functional group in all PC 
axes (Fig.5A). The distance by which individual cell lines are repositioned then depends on 
the combined amounts of its targets (Bcl-2+Bcl-xL) (Fig.5B). The resulting repositioning 
vectors were applied to four representative cell lines that poorly respond to TRAIL (RPM-EP, 
RPM-MC, MeWo, Preyer). For the TRAIL-resistant MeWo and Preyer cells, the vectors 
pointed in the direction of cell lines that are moderately TRAIL sensitive (yellow) (Fig.5C), 
indicating that addition of ABT-737 may enhance TRAIL responsiveness. In contrast, for the 
poor TRAIL responders RPM-EP or RPM-MC the vectors did not result in a movement 
towards regions of higher TRAIL responsiveness (Fig.5C). The predictions on high vs. low 
sensitization by ABT-737 for these four cell lines were validated experimentally. As 
predicted, ABT-737 strongly sensitized MeWo and Preyer cells to TRAIL, whereas 
sensitization of RPM-EP and RPM-MC was far less pronounced (Fig.5D). Control 
experiments ensured that ABT-737 readily entered all cell lines and was capable to sensitize 
these for mitochondrial translocation of ectopically expressed YFP-Bax (Supplemental 
Fig.5). We next applied the same approach to a scenario of siRNA-mediated XIAP depletion. 
Our calculations on movement direction and movement distance (Fig.5E,F) suggested that 
out of four poor TRAIL responders (Preyer, MeWo, RPM-EP, MM-AN) only MM-AN could 
be relocated closer to cell lines with higher TRAIL responsiveness (Fig.5G). Again, these 
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predictions were confirmed by subsequent experiments. Even though XIAP was efficiently 
depleted, as confirmed by immunoblotting (Fig.5H), using a previously validated siRNA 
sequence 27-28, only MM-AN cells were significantly sensitized to TRAIL (Fig.5H). These 
results therefore demonstrate that accurate predictions can be made on which proteins should 
be targeted to efficiently enhance cellular responsiveness of individual cell lines that poorly 
respond to TRAIL.  
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Discussion 
The elimination of cancer cells by cell death induction is a mainstay of anti-cancer 
chemotherapies 29 and is likely an important predictor if treatment modalities such as immune 
therapy can be effective to control disease relapse. Apoptotic cell death is an irreversible cell 
fate decision, and is regulated by the complex interplay of multiple proteins that control 
signal transduction during the initiation and execution phases of programmed cell death. 
Here, we integrated quantitative information on systems-level protein interplay with 
multivariate statistical analysis and pattern recognition algorithms in order to generate 
predictions on the susceptibility of melanoma cell lines to TRAIL and DTIC (Fig.6). These 
predictions were highly accurate (91% and 82% correct predictions) and outperformed the 
predictive capacity of a systems knowledge-independent statistical analysis (55% and 36% 
prediction accuracy). Our findings indicate that to reliably predict cell death responsiveness 
the multi-factorial control of apoptosis signaling needs to be taken into account, and that this 
can be achieved by integrating systems-level pathway knowledge into the analysis of protein 
expression patterns.  
Our knowledge- and data-driven modeling approach was successfully applied for drug 
treatments that are known to induce extrinsic and intrinsic apoptosis, and controls with 
caspase inhibitor zVAD-fmk in selected responsive cell lines demonstrated that apoptosis 
was the primary cell death modality (Supplemental Fig.S3). Performance scores were very 
high for TRAIL-induced cell death, which may be attributable to our quantitative 
measurements having covered all critical TRAIL signal transducers. Furthermore, TRAIL-
induced apoptosis can proceed independent of protein neosynthesis, explaining why a 
systems analysis of baseline protein expression is sufficient to accurately predict TRAIL 
responsiveness. Since TRAIL ligands are currently investigated in clinical trials and since 
improved 2nd generation ligands are currently in preclinical development 30-31, our systems 
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approach may provide possibilities to identify TRAIL-responsive melanoma by molecular 
profiling, and by extension may assist in patient stratification as part of future clinical trial 
designs. We were also able to predict DTIC-induced cell death, albeit with slightly lower 
accuracy. The induction of apoptosis by genotoxic stress is mediated by p53-dependent 
transcriptional induction of BH3-only proteins such as Noxa, Puma and Bik 32-33. Baseline 
expression amounts of these BH3-only proteins are typically very low, and p53 is rarely 
mutated in melanoma (<5%) 34. This may explain why we achieved predictive capacity for 
DTIC treatments as well, even though we did not measure BH3-only protein amounts other 
than Bid. However, Bid has been reported to also contribute to genotoxic apoptosis 35, and in 
this context is cleaved by death receptor-independent, presumably ripoptosome-activated 
caspase-8 36-37. A more comprehensive profiling of BH3-only proteins may nevertheless 
further enhance the performance scores, and including information on the p53 mutational 
status will be required when further developing this approach for cancer entities in which p53 
is more frequently mutated. Likewise, molecular coverage of alternative cell death 
mechanisms, such as necroptosis signaling, may further improve the performance of our 
approach since in our measurements we captured total cell death rather than only specific 
apoptotic cell death. Such an expansion could therefore be particularly important at 
conditions where apoptosis-independent cell death signaling plays a substantial role 38-39. 
Various previous studies suggested that abundance measurements of proteins which regulate 
apoptosis in melanoma, including anti-apoptotic Bcl-2 family members and XIAP 40-41, may 
be sufficient to predict cell death susceptibility. Our study instead demonstrates that apoptosis 
susceptibility depends on the quantitative interplay of multiple proteins, and that targeted 
interventions to enhance apoptosis responsiveness need to be identified on a case-by-case 
basis. Our study also highlights that due to the heterogeneity in apoptosis protein expression a 
single optimal treatment strategy cannot be suggested for a given tumor entity, as exemplified 
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by malignant melanoma. Since we have investigated a large number of proteins (n=17) in a 
large panel of cell lines (n=11) by quantitative measurements, the biological heterogeneity in 
apoptosis protein expression and cell death responsiveness in melanoma model systems may 
have been more representatively captured in our study than was the case in previous reports. 
Importantly, despite the heterogeneity in protein expression, our systems-level data analysis 
allowed us to obtain insight into both drug responsiveness and resistance mechanisms of 
individual cell lines. Together, these findings may have important implications for future 
translational biomarker identification strategies in the field of melanoma and other highly 
heterogeneous cancers. Since the classical repertoire of preclinical and clinical statistical 
biomarker screening so far yielded surprisingly few biomarkers that successfully translated 
into clinical practice 3, integrating systems level information and data analysis approaches 
may contribute to improving this situation in the future.  
It can be speculated that our approach could be used to analyze primary tumors or metastases 
for their capacity to execute apoptosis, to predict therapy responsiveness, and to generate 
personalized treatment recommendations. However, a validation for clinical application at the 
present time is challenging due to the need for large scale, quantitative protein expression 
analysis. Commonly used tissue immunohistochemistry in clinical diagnostics, based on 
immunoperoxidase staining, is of limited dynamic range, and stained tissue slides are 
typically not calibrated for quantitative readouts. Sufficient fresh frozen tissue as required for 
quantitative immunoblotting is rarely collected or available, and reverse phase protein arrays, 
which can be applied for large-scale multi-sample protein quantification in clinical specimens 
42, require the prior identification or development of high quality antibodies for each protein 
of interest. A successful clinical implementation of pathway-based systems models will 
furthermore necessitate the integration with mathematical models that cover higher level 
aspects that are known to critically influence therapy responsiveness and outcome. These 
17 
 
include for example models reflecting drug pharmacokinetics and pharmacodynamics, tumor 
vascularization, and information on the tumor microenvironment and immune infiltration. 
Higher scale modeling strategies that can make use of such information have been described 
in recent years 10, 43 and have the potential to be linked to systems models that have been 
validated in cellulo. Likewise, models that capture cell survival due to treatment-induced 
changes in protein expression profiles44 would be valuable tools that in the future could be 
combined with our approach and that may serve to better predict chemotherapy efficacy. Our 
study may therefore make an important contribution towards developing systems-based 
predictive tools that can be applied in a clinical context in the future.  
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Experimental Procedures 
 
Materials: Dacarbazine (DTIC) was purchased from Sigma-Aldrich Ireland Ltd (Dublin, 
Ireland), ABT-737 was from Biorbyt (Riverside, UK), Mitotracker Red was from Invitrogen 
(UK). Human recombinant TRAIL was a generous gift from Carlos Ricardo Rodrigues dos 
Reis, University of Groningen. 
 
Cell Culture and Drug Treatments: The human melanoma cell lines PM-WK, RPM-MC, 
RPM-EP, MM-RU, MM-AN, and MM-LH were generously provided by Randy H. Byers 
(Boston University School of Medicine, Department of Dermatology) and cultured as 
previously described 45. The following human melanoma cells were obtained either from 
ATCC or DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) and 
cultured as described: A375 (ATCC CRL-1619), MeWo (ATCC HTB-65), SK-Mel-30 (SK-
Mel; ACC 151), and IGR-37 (IGR; ACC 237). Preyer melanoma cells (generated from a 
subcutaneous melanoma metastasis) were kindly provided by A. Schwaaf and E.B. Bröcker, 
University of Würzburg, Germany). All melanoma cell lines were cultured in DMEM 
(Lonza, Slough, UK) supplemented with 4 mM L-glutamine, 4.5 g/l glucose, 10% (w/v) heat-
inactivated fetal bovine serum (Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma-Aldrich) as published 46. Cells were grown at 5% CO2 and 37○C. For 
cell death analysis, cells were incubated for 24 h with TRAIL (100 ng/ml) or for 48 h with 
DTIC (1 mg/ml).  
 
Transfections: siRNA known to specifically silence the expression of XIAP and non-
silencing control sequences were obtained by Sigma-Aldrich (XIAP: AAG UGG UAG UCC 
UGU UUC AGC 28; control: UUC UCC GAA CGU GUC ACG U[dT]). Cells were 
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transfected with siRNA (100 nM) in Optimem with Lipofectamine 2000 (Invitrogen, Paisley, 
UK) according to the manufacturer’s instruction at least 24 h prior to drug treatment. Protein 
depletion was validated by immunoblotting. Transient transfections for the expression of 
YFP-Bax were conducted as described before 47 and cell were analyzed by conventional 
widefield fluorescence microscopy.  
 
Immunoblotting and Densitometry: Cells were harvested, washed in PBS and 
homogenised in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 10% (v/v) glycerin, 2% (w/v) SDS, 
1 mM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin and 5 g/ml aprotinin). Lysates were 
heated to 95○C for 15 min and cleared of debris by centrifugation. Protein content was 
assayed using the Micro BCA protein assay kit (Thermo Scientific, Dublin, Ireland). Samples 
(20 μg) were resolved on 10-15% SDS-polyacrylamide gels (150 V for approximately 1 h). 
Proteins were transferred to nitrocellulose membranes (Whatman, Kent, UK) in transfer 
buffer (25 mM Tris, 192 mM glycine, 20% methanol (v/v) and 0.01 (w/v) SDS) at 18 V for 
1.5 h. Membranes were blocked in 5% nonfat dry milk in distilled water at room temperature 
for 1 h and incubated with primary antibodies overnight at 4○C. Membranes were then 
washed with TBST three times for 5 min and incubated with anti-mouse, anti-rabbit or anti-
goat peroxidase-conjugated secondary antibodies (Millipore, Molsheim, France). The 
following primary antibodies were used: a rabbit polyclonal APAF-1 antibody (No. 559683, 
BD Transduction Laboratories, San Jose, CA, USA), a rabbit polyclonal Bak antibody (sc-
832, Santa Cruz Biotechnology), a rabbit polyclonal Bax antibody (No. Q07815, Millipore), a 
mouse monoclonal Bcl-2 antibody (sc-509, Santa Cruz Biotechnology), a mouse monoclonal 
Bcl-XL antibody (sc-8392, Santa Cruz Biotechnology), a goat polyclonal Bid antibody 
(AF860, R&D Systems), a rabbit polyclonal caspase-3 antibody (#9662, Cell Signaling 
Technology, Danvers, MA, USA), a mouse monoclonal caspase-8 antibody (No 804-242, 
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Alexis, San Diego, CA, USA), a rabbit polyclonal caspase-9 antibody (No. 218794, 
Calbiochem /Merck Bioscience, Nottingham, UK), a mouse monoclonal cytochrome-c 
antibody (No. 556433, BD Transduction Laboratories), a mouse monoclonal DR4 antibody 
(ab47138, AbCam), a rabbit polyclonal DR5 antibody (No 804-298, Alexis San Diego, CA, 
USA), a mouse monoclonal FADD antibody (No. 610399, BD Transduction Laboratories), a 
mouse monoclonal FLIP antibody (No 804-428, Alexis), a mouse  monoclonal Mcl-1 
antibody ((No. 559027, BD Transduction Laboratories), a rabbit polyclonal SMAC/Diablo 
antibody (AF789, R&D Systems), a mouse monoclonal XIAP antibody (No 610763, BD 
Transduction Laboratories), a mouse monoclonal β-actin antibody (A5441, Sigma-Aldrich). 
Anti-mouse IgG, anti-goat IgG, anti-rabbit IgG peroxidase conjugated secondary antibodies 
(AP124P, AP106P, AP132P, Millipore) were used at a dilution of 1:5000 for 1 h. Blots were 
washed and developed using the Immobilon™ western chemiluminescence HRP substrate 
(Millipore). Chemiluminescence was detected at a depth of 12-bit in the linear detection 
range of a Fuji LAS 4000 CCD system (Fujifilm UK Ltd., Bedfordshire, UK). Special care 
was taken not to overexpose in order to guarantee accurate quantifications. For all proteins at 
least three independent membranes were analysed. Densitometry was performed on 12-bit 
raw images using ImageJ 1.4.1o software (National Institute of Health, USA, 
http://rsb.info.nih.gov/ij) 48. For each protein, the integrated density of the signal was 
measured, corrected for background signals and adjusted to loading controls. Intensities were 
then compared to signals obtained from HeLa cell extracts run on the same gels. Absolute 
protein levels in HeLa cells (nM) have been determined by us and others before by 
comparison to titrated purified proteins 48; Lindner et al., 2012). For visual presentation, 12-
bit images were contrast adjusted and converted to 8-bit.  
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Flow cytometry: Flow cytometry was performed on a BD LSRII flow cytometer (BD 
Bioscience, Oxford, UK) equipped with a high throughput system (HTS) to acquire samples 
directly from 96 well plates. DR-4 and DR-5 surface expression was assessed by indirect 
immunofluorescence. Briefly, cells were harvested, washed, fixed in 4% paraformaldehyde in 
PBS for 15 min and incubated with a mouse monoclonal DR4 (AbCam) or DR5 antibody 
(Alexis) (5 μg/106 cells) for 30 min followed by secondary anti-mouse FITC-conjugated 
antibody (AbCam) (1:50 dilution) for 30 min in the dark. Controls were stained with 
secondary antibody only. After each incubation, cells were washed with 3% BSA in PBS to 
remove excess antibody. FITC was excited at 488 nm and fluorescence emission was 
collected through a 552/50 nm band-pass filter and a 505 nm long pass filter. The relative 
expression of death receptors was determined by comparison of specific staining intensities. 
For cell death measurements, cells were detached and incubated on an orbital shaker (300 
rpm) with propidium iodide (2 μg/ml) (Sigma-Aldrich) at room temperature for 15 min in the 
dark. Propidium iodide was excited with a 561 nm laser line and fluorescence emission was 
collected through a 605/40 nm band-pass filter and a 570 nm long pass filter. Data were 
analysed using Cyflogic software (CyFlo Ltd, Turku, Finland). Cell death measurements 
were conducted as endpoint readings. Control experiments in selected high and low 
responding cell lines were performed at multiple time points with AnnexinV-FITC 
(Biovision, CA)/propidium iodide co-staining to ensure the absence of significant amounts of 
early apoptotic cells (Annexin V+/PI-) at the time of measurement.  
 
Data processing and analysis for knowledge- and data-driven modeling: All data 
processing and analysis was performed using a programming code developed for MATLAB 
2007b (The Mathworks, UK), equipped with the statistics toolbox. Protein data in functional 
groups were rescaled prior to statistical analysis by dividing through the respective standard 
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deviation, followed by mean centering. A principal component analysis (PCA) based on the 
correlation matrix of these data was performed 19-20. The Kaiser criterion and an adapted 
scree plot were used to identify how many principal components needed to be retained for 
subsequent analyses 21-22. For visualizations, scatter plots were generated from the first three 
principle components. Cell lines were assigned to classes of cell death responsiveness using 
k-means clustering. Linear Discriminant Analysis 24 was performed in the first four principle 
components to determine the quality of response class separation in the PC space. To 
determine predictive capacity, leave-one-out cross-validation (LOOCV) was applied 
iteratively on training sets of 10 cell lines, with the remaining cell line being the test set. The 
test cell line was placed into the PC space according to its specific functional group values 
and associated PC coefficients calculated from the training cell lines. LDA was applied to 
determine whether the test cell line positioned in the spatial region that corresponded to its 
drug responsiveness. To predict the consequences of targeted protein perturbations, the target 
protein concentrations were set to zero, and the displacement of individual cell lines was 
calculated by multiplying the changes in the respective functional groups with the 
coefficients in the first three PCs. Movement towards spatial regions of higher responsiveness 
were considered to be predictive of sensitization.  
 
Statistical Testing: Student’s t-tests were used to identify statistically significant differences 
between treatment groups. p-values above 0.05 were considered not to be significant. p-value 
ranges below 0.05 were indicated in the respective figure panels. Analyses were performed 
using SPSS 15 (Lead Technologies Inc.).  
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Figure Legends 
 
Fig.1: Coding and parameterising functional groups of apoptosis signal proteins for 
knowledge- and data-driven systems modelling.  
(A) Pathway diagram of extrinsic apoptosis signal transduction through the TRAIL pathway.  
(B) Combination of apoptosis signalling proteins into functional groups by simple arithmetic 
operations. (C) Relative levels of protein expression within the melanoma cell line panel. 
Circles summarize 612 quantifications and circle sizes are proportional to the protein 
quantities determined from n=3 independent detections each. Green and red indicate anti- and 
pro-apoptotic proteins, respectively. Absolute protein amounts are provided as Supplemental 
Table 1.  
 
Fig.2: Functional groups of apoptosis regulators highlight an association between 
protein expression profiles and cell death responsiveness to TRAIL and DTIC. 
(A) A Principal component analysis (PCA) was applied to the functional groups of the 
melanoma cell line panel, and results are shown as a scree plot. Bar graphs show the 
contribution of each principal component (PC) towards explaining the data variance. 
Eigenvalues of PCs fulfilling the Kaiser criterion are shaded in grey. (B) Bar graphs show the 
coefficients for all functional groups in the first four PCs. Coefficient values are provided as 
Supplemental Table 2. (C) Graphical illustration of the distribution of melanoma cell lines 
along the first three PCs. Circle sizes decrease with distance from the observer to aid 3D 
visualization. (D) Cell death in response to TRAIL or DTIC. Cells were treated for 48 h and 
cell death was measured by propidium iodide uptake. Data are means + s.d. above untreated 
controls and were pooled from n=3 independent repeat experiments. (E,F) Cell lines in the 
3D PC space were color coded according to cell death responsiveness to TRAIL or DTIC, 
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respectively. Color codes reflect resistance (black), low responsiveness (red), or medium 
responsiveness (yellow). Cell lines with high responsiveness (green) were not detected. 3D 
rotations are available as Supplementary Movies 1 and 2. (G) Linear Discriminant Analysis 
(LDA) was applied to the 4-dimensional PC space. The 2D schematic visualizes the principle 
of separating response regions by this pattern recognition approach. (H) The performance of 
the response group separation in the 4-dimensional space by LDA is shown by listing the 
amounts of correctly classified cell lines.  
 
Fig.3: Systems analysis generates highly accurate case-specific predictions on TRAIL 
and DTIC responsiveness of melanoma cell lines.  
(A) Determination of predictive power by leave-one-out cross-validation (LOOCV). 2D 
projections of 3D PC spaces calculated from combinations of 10 cell lines are shown. LDA 
was applied to define spatial regions for resistant cell lines, low and medium responders for 
TRAIL treatment. Circle sizes decrease with distance, thereby representing the third PC 
dimension. Test cell lines (open circles, highlighted by arrows) were placed into the 
respective PC spaces according to their functional group values. If test cell lines positioned in 
spatial regions that were defined by prior LDA to correspond to their drug responsiveness, 
their responsiveness was considered to be predicted correctly. (B) Performance scores for 
correctly predicting drug responsiveness of test cell lines to TRAIL or DTIC by LOOCV-
PCA and LDA in 4-dimensional space.  
 
Fig.4: Case-specific predictions on TRAIL and DTIC responsiveness allow the in silico 
identification of optimal treatment options.  
The predictive capacity of the systems approach was exploited as a treatment decision tool. 
Treatment recommendations were made in silico according to highest predicted 
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responsiveness to DTIC or TRAIL, respectively. Predictions were validated against 
experimental data. Predictions were labeled as correct (green) when the best treatment option 
could be identified, prediction were labeled as wrong (red) when the possibility existed that 
the better treatment option could be missed.  
 
Fig.5: Prediction and experimental validation of targeted perturbations that sensitize 
poorly responding cell lines to TRAIL. 
(A-D) Targeted perturbation with Bcl-2/Bcl-xL antagonist ABT-737. (A) Inverse vectorial 
addition of the coefficients of the Bcl-2+Bcl-xL+Mcl-1 functional group in the first 3 PCs. 
The resultant vector is shown in red and indicates the direction of cell line displacement in 
the PC space upon antagonizing this functional group by ABT-737. (B) Bar graphs show the 
distance by which individual cell lines are displaced in the 3D PC space when neutralizing 
Bcl-2 and Bcl-xL by ABT-737. (C) Combination of movement direction and distance shown 
in the 3D PC space for four poorly TRAIL-responsive cell lines. (D) Experimental validation 
of sensitization predictions. Cells were treated with 100 ng/ml TRAIL and/or 5 µM ABT-737 
as indicated. Data show cell death above untreated controls (means + s.d. from n=3 
independent experiments). Student’s t-test was used for statistical analysis. (E-H) Targeted 
perturbation by siRNA-mediated XIAP depletion. (E) The red vector indicates the direction 
of cell line displacement by XIAP depletion. (F) Bar graphs indicate the distance of 
movement of individual cell lines in the 3D PC space upon eliminating XIAP. (G) 
Combination of movement direction and distance shown in the 3D PC space for four poorly 
TRAIL-responsive cell lines. (H) Experimental validation of sensitization predictions. Cells 
were treated with 100 ng/ml TRAIL 24 h after transfection with 100 nM XIAP siRNA or 
scrambled control siRNA. Data show cell death above controls transfected with scrambled 
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siRNA (means + s.d. from n=3 independent experiments). Student’s t-test was used for 
statistical analysis. Immunoblot inserts show the efficacy of XIAP depletion by siRNA. 
 
Fig.6: Workflow and associated functionalities for data- and knowledge-driven systems 
modeling to predict apoptosis sensitivity and treatment options.  
The systems analysis of apoptosis protein expression allowed (i) to predict responsiveness of 
melanoma cell lines to TRAIL and DTIC, (ii) to predict optimal treatment options for 
individual cell lines, and (iii) to successfully identify targeted interventions that increased 
apoptosis responsiveness in treatment-resistant cells.  
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